2573-30-0

Basic information

• Product Name: ethyl N-(3-fluorophenyl)glycinate
• CAS NO: 2573-30-0
• Molecular Formula: C₁₀H₁₂FNO₂
• Molecular Weight: 197.2062
• Mol File: 2573-30-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 277.2°C at 760 mmHg
• Flash Point: 121.4°C
• Density: 1.187g/cm³
• Vapor Pressure: 0.0046mmHg at 25°C
• Refractive Index: 1.532
• CAS DataBase Reference: ethyl N-(3-fluorophenyl)glycinate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl N-(3-fluorophenyl)glycinate(2573-30-0)
• EPA Substance Registry System: ethyl N-(3-fluorophenyl)glycinate(2573-30-0)

Safety Data

• Hazardous Substances Data: 2573-30-0(Hazardous Substances Data)

Usage

General Description

Ethyl N-(3-fluorophenyl)glycinate is a chemical compound with the formula C10H12NO2F. It is a white to off-white powder used primarily as an intermediate in the synthesis of pharmaceuticals and agrochemicals. ethyl N-(3-fluorophenyl)glycinate is a glycine derivative, with an ethyl ester group attached to the amino group and a 3-fluorophenyl group attached to the alpha carbon. It has potential applications in the development of new drugs and veterinary medicine due to its ability to modify biological activities. Ethyl N-(3-fluorophenyl)glycinate may also have applications as a building block in organic synthesis for the production of various chemical products.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 372-19-0 meta-fluoroaniline 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 5319-43-7 2-(3-fluorophenylamino)acetic acid 

Relevant articles and documents

Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage

So far, there is still no specific drug against COVID-19. Taking compound 1 with anti-EBOV activity as the lead, fifty-four 12N-substituted aloperine derivatives were synthesized and evaluated for the anti-SARS-CoV-2 activities using pseudotyped virus model. Among them, 8a exhibited the most potential effects against both pseudotyped and authentic SARS-CoV-2, as well as SARS-CoV and MERS-CoV, indicating a broad-spectrum anti-coronavirus profile. The mechanism study disclosed that 8a might block a late stage of viral entry, mainly via inhibiting host cathepsin B activity rather than directly targeting cathepsin B protein. Also, 8a could significantly reduce the release of multiple inflammatory cytokines in a time- and dose-dependent manner, such as IL-6, IL-1β, IL-8 and MCP-1, the major contributors to cytokine storm. Therefore, 8a is a promising agent with the advantages of broad-spectrum anti-coronavirus and anti-cytokine effects, thus worthy of further investigation.